// App-Quantinova.ai

2098 : Understanding the synergy between temozolomide and PARP inhibition in Ewing sarcoma

Researchers

Presenter

  • Ruth Carlson

Principal Investigators

  • Raushan Kurmasheva

Medical Centers

  • University of Texas Health Science Center San Antonio, San Antonio, TX

Locations

  • United States

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Mismatch repair deficiency

  • Ewing's sarcoma

  • Sarcoma

  • Solid malignancies

Biomarkers

  • Poly(ADP-Ribose) Polymerase 1

Drug/Treatment

  • Temozolomide

  • BMN-673

  • BMN 673

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved